CDC: RSV vaccine is effective in infants

The Centers for Disease Control and Prevention this week released data showing nirsevimab, a long-acting monoclonal antibody, protected infants with RSV from hospitalization. The finding supports CDC recommendation to give infants nirsevimab if the mother did not receive the maternal RSV vaccine during pregnancy. Using early data from the CDC’s population-based surveillance platform that monitors pediatric respiratory viruses to assess immunization effectiveness, the study evaluated 699 infants from October 2023 through February 2024. Nirsevimab was 90% effective at preventing RSV-associated hospitalizations in infants during their first RSV season. (CDC news release, 3/11/24)